Cargando…

MicroRNAs in melanoma development and resistance to target therapy

microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5′ end of a 21-23 nt...

Descripción completa

Detalles Bibliográficos
Autores principales: Fattore, Luigi, Costantini, Susan, Malpicci, Debora, Ruggiero, Ciro Francesco, Ascierto, Paolo Antonio, Croce, Carlo M., Mancini, Rita, Ciliberto, Gennaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400662/
https://www.ncbi.nlm.nih.gov/pubmed/28118616
http://dx.doi.org/10.18632/oncotarget.14763
_version_ 1783230897175134208
author Fattore, Luigi
Costantini, Susan
Malpicci, Debora
Ruggiero, Ciro Francesco
Ascierto, Paolo Antonio
Croce, Carlo M.
Mancini, Rita
Ciliberto, Gennaro
author_facet Fattore, Luigi
Costantini, Susan
Malpicci, Debora
Ruggiero, Ciro Francesco
Ascierto, Paolo Antonio
Croce, Carlo M.
Mancini, Rita
Ciliberto, Gennaro
author_sort Fattore, Luigi
collection PubMed
description microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5′ end of a 21-23 nt sequence with a partially complementary sequence located in the 3′ untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors.
format Online
Article
Text
id pubmed-5400662
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-54006622017-05-03 MicroRNAs in melanoma development and resistance to target therapy Fattore, Luigi Costantini, Susan Malpicci, Debora Ruggiero, Ciro Francesco Ascierto, Paolo Antonio Croce, Carlo M. Mancini, Rita Ciliberto, Gennaro Oncotarget Review microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes. Their mechanism of action is primarily based on the imperfect matching of a seed region located at the 5′ end of a 21-23 nt sequence with a partially complementary sequence located in the 3′ untranslated region of target mRNAs. This leads to inhibition of mRNA translation and eventually to its degradation. Individual miRNAs are capable of binding to several mRNAs and several miRNAs are capable of influencing the function of the same mRNAs. In recent years networks of miRNAs are emerging as capable of controlling key signaling pathways responsible for the growth and propagation of cancer cells. Furthermore several examples have been provided which highlight the involvement of miRNAs in the development of resistance to targeted drug therapies. In this review we provide an updated overview of the role of miRNAs in the development of melanoma and the identification of the main downstream pathways controlled by these miRNAs. Furthermore we discuss a group of miRNAs capable to influence through their respective up- or down-modulation the development of resistance to BRAF and MEK inhibitors. Impact Journals LLC 2017-01-19 /pmc/articles/PMC5400662/ /pubmed/28118616 http://dx.doi.org/10.18632/oncotarget.14763 Text en Copyright: © 2017 Fattore et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Review
Fattore, Luigi
Costantini, Susan
Malpicci, Debora
Ruggiero, Ciro Francesco
Ascierto, Paolo Antonio
Croce, Carlo M.
Mancini, Rita
Ciliberto, Gennaro
MicroRNAs in melanoma development and resistance to target therapy
title MicroRNAs in melanoma development and resistance to target therapy
title_full MicroRNAs in melanoma development and resistance to target therapy
title_fullStr MicroRNAs in melanoma development and resistance to target therapy
title_full_unstemmed MicroRNAs in melanoma development and resistance to target therapy
title_short MicroRNAs in melanoma development and resistance to target therapy
title_sort micrornas in melanoma development and resistance to target therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400662/
https://www.ncbi.nlm.nih.gov/pubmed/28118616
http://dx.doi.org/10.18632/oncotarget.14763
work_keys_str_mv AT fattoreluigi micrornasinmelanomadevelopmentandresistancetotargettherapy
AT costantinisusan micrornasinmelanomadevelopmentandresistancetotargettherapy
AT malpiccidebora micrornasinmelanomadevelopmentandresistancetotargettherapy
AT ruggierocirofrancesco micrornasinmelanomadevelopmentandresistancetotargettherapy
AT asciertopaoloantonio micrornasinmelanomadevelopmentandresistancetotargettherapy
AT crocecarlom micrornasinmelanomadevelopmentandresistancetotargettherapy
AT mancinirita micrornasinmelanomadevelopmentandresistancetotargettherapy
AT cilibertogennaro micrornasinmelanomadevelopmentandresistancetotargettherapy